<b>Background:</b> Ribociclib, initially approved for HR+/HER2- advanced breast cancer (ABC) at a 600 mg dose, was recently approved for HR+/HER2- early breast cancer (EBC) at a 400 mg dose based on the NATALEE trial. This evidence concerns the gene ERBB2 and breast carcinoma.